2026-525700-10-00RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Jun 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- First submitted
- 6 Mar 2026
- Start date
- 8 Jun 2026
- Lead sponsor
- Syremis Therapeutics Ltd.
- EU CT number
- 2026-525700-10-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 280
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adult volunteers to test the safety and effects of ST‑905‑AG1.
- Age
- 18 Years to 64 Years
- Sex
- All sexes can join.
This trial only enrols healthy participants. The registry sentence this rests on: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Biotrial | Rennes | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.